• $MNAI ·  
  • By clicking "Subscribe", you agree to our Disclaimer and Privacy Policy.

    Penny Stocks To Watch For April 27th 2010 POSC IGC MCET HNAB ARSC IGNT

    Written by:

    Bookmark and Share

    www.TheStockWizards.net: The Stock Wizards  Announces It’s Micro Cap Penny Stocks Movers & Shakers !!  POSC IGC MCET  HNAB ARSC IGNT

    THE STOCK WIZARDS FOCUS LISTS INCLUDES: (OTCBB: POSC) Positron Corp., (AMEX: IGC) India Globalization Capital, Inc., (OTCBB: MCET) MultiCell Technologies, Inc., (OTCBB: HNAB) Hana Biosciences, Inc., (OTC: ARSC) American Security Resources Corp., (OTC: IGNT) Ingen Technologies, Inc.

    Stop by Our Website at http://www.TheStockWizards.net and Get Educated on How To Make Big Money Trading Penny Stocks.

    Check Out Our New Traders Tool Bar!! http://bit.ly/d7MEov

    +++++++++++++++++++++++

    (OTCBB: POSC) Positron Corp.)

    CURRENT NEWS!!

    Update: Positron Corporation Announces CEO Agenda for Media and Analyst Conference

    NEW YORK, Apr 27, 2010 Positron Corporation (OTCBB:POSC), a molecular imaging solutions company focused on Nuclear Cardiology, today announced that its CEO Patrick G. Rooney and senior executives will present at the NASDAQ Market Site in Times Square, New York City, NY.

    Topics to include: The Company will introduce business initiatives and certain strategic alliances with industry leading companies and will address how certain opportunities will impact the industry and the Company.

    Senior Executives will discuss the Company’s leadership role in the Nuclear Medicine industry and the immediate demand driving Cardiac PET (positron emission tomography) as a result of many positive industry factors pushing Cardiac PET as the preferred nuclear cardiology imaging modality. In addition, Positron Executives will discuss the Company’s revolutionary radiopharmaceutical distribution devices as to how they enable disintermediation by manufacturers, wholesalers and consumers alike.

    Additional information will be given about the Company’s patient injection device as it applies to patient care and worker safety with oncology and cardiology therapeutic and diagnostic radiopharmaceuticals.

    When: May 5, 2010, 1:00 pm EDT

    Where: NASDAQ MarketSite, 4 Times Square, New York, NY

    RSVP required for building security: or christina.flood@muncmedia.com

    Click here to watch the event 5/5, 1:00pm

    Positron Corporation executives will be available for interviews. Please call 917 / 680 – 6011 to schedule.

    About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging systems to radiopharmaceutical distribution. Positron products include: the Attrius(TM), a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the Tech-Assist(TM), a radiopharmaceutical injection shield. As a prominent player in the cardiac imaging industry, Positron maintains associations and relationships with multiple industry associations including the Academy of Molecular Imaging, American College of Cardiology American Society of Nuclear Cardiology and Society of Nuclear Medicine. Positron founded in 1983, is headquartered in Indianapolis, Indiana. More information about Positron is available at www.positron.com.

    +++++++++++++++++++++++++++++++

    (IGC: AMEX India Globalization Capital, Inc.)

    CURRENT NEWS!!

    India Globalization Capital Announces $160 Million, 5 Year Iron Ore Supply Contract With Leading Chinese Steel Manufacturer

    BETHESDA, MD, Apr 27, 2010 India Globalization Capital, Inc. (NYSE Amex: IGC), a rapidly growing materials and infrastructure company in India, announced today they have signed a 5 year contract with a leading Chinese steel manufacturer, to begin supplying iron ore. The contract is valued at approximately $160 million.

    Under the agreement, IGC will deliver 63.5 percent ferrous content iron ore, initially 40,000 Metric Tons (MT) per ship load, building up to 80,000 MT per shipload up to an aggregate of 1,600,000 MT over the life of the contract. The iron ore will be supplied from mines in India and shipped out of the Visakhapatnam port, off the eastern coast of India and out of Karwar on the west coast.

    Ram Mukunda, Chief Executive Officer of India Globalization Capital, commented, “Our Chinese customer is a large steel manufacturing and trading company, established in 2001 and located near Shanghai with 2008 revenue of over $500 million. With this significant contract, we now have a backlog of $160 million in our ore business, which we will begin to ship in this quarter. We have quickly become a meaningful supplier of iron ore, attracting high caliber customers. We believe that the materials side of our business, export of ore, and supply of rock aggregate is now poised for significant growth in this fiscal year.”

    China is the world’s largest importer of iron ore and the biggest producer of steel. India is the third largest supplier of ore to China.

    About India Globalization Capital India Globalization Capital is a materials and infrastructure company operating in India. We build roads, bridges and highways, and provide materials to the infrastructure industry in India and China. The Company has offices in Maryland, Mauritius, Nagpur, Cochin, Delhi, and Bangalore. For more information about India Globalization Capital, please visit www.indiaglobalcap.com.

    +++++++++++++++++++++++++++++++++

    (OTCBB: MCET  Multi Cell Technologies, Inc.)

    CURRENT NEWS!!

    MultiCell Technologies Is Granted European Patent for the Treatment of Cancer

    , cancer, autoimmune, and infectious diseases, announced it will host a media & analyst conference.

    WOONSOCKET, R.I., April 26, 2010 MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today that it has been granted a European patent (EP 1539819B1) covering certain of its therapeutic candidates for the treatment of cancer.

    Increasing evidence suggests that the immune system regulates the development of cancer by several mechanisms. This regulation can be either beneficial through immuno surveillance and the destruction of cancer cells, or detrimental by facilitating tumor growth by shaping the immuneophenotype of tumors, creating an immunosuppressive environment, or inducing regulatory T-cells.

    MultiCell has created a new class of recombinant antibody therapeutics which redirect the immune response to specific cancer targets corresponding to the peptides engrafted onto the recombinant antibody. Such compositions are able to transform seemingly ineffective peptides into potent antibody therapeutics with a different mechanism of action compared to that of conventional antibody therapeutics currently in clinical use. These recombinant antibody therapeutics not only produce a potent immune response, but also stimulate the generation of cytolytic cells, and Interferon-gamma and Interleukin-2 producing T-cells. When coupled with MultiCell’s dsRNA therapeutics, this new class of recombinant antibody therapeutics has been shown in animal models to eradicate cancer and generate immune protection against the reoccurrence of malignant tumors.

    “We are very pleased that the European Patent Office has decided to grant us a patent covering our novel compositions and method for the treatment of cancer as well as for the treatment of infectious disease,” stated Jerry Newmin, Chairman and Chief Executive Officer of MultiCell Technologies. “Our technology uses the antibody molecule as a platform to better present a peptide to immune cells thereby increasing the overall immune response to the peptide,” Mr. Newmin added.

    MultiCell also owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), one U.S. patent application (U.S. 2006/0019387A1), and several corresponding issued and pending foreign patents and patent applications related to the isolation and differentiation of liver stem cells. The role of liver stem cells in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. In addition, liver cancer and cancerous stem cells specifically, are amenable to targeted therapeutic approaches including peptide-directed immunotherapy.

    Primary liver cancer begins in the cells of the liver itself. According to the National Cancer Institute (NCI), in 2008 there were approximately 21,400 new cases of primary liver cancer and intrahepatic bile duct cancer in the United States, and approximately 18,400 of those cases resulted in death. Hepatocellular carcinoma, resulting from Hepatitis B and Hepatitis C infection, is the most common cancer in some parts of the world, with more than 1 million new cases diagnosed each year. The NCI also reports that hepatocellular carcinoma is associated with cirrhosis of the liver in 50% to 80% of patients.

    About  MultiCell Technologies, Inc.

    MultiCell Technologies, Inc., is a leading provider of liver cell-based products for drug discovery and therapeutic applications. The Company specializes in innovative cell immortalization technologies for reproducible creation of highly functional cell lines. MultiCell is now marketing liver cell lines via licensee, XenoTech, LLC and has additional pipeline products.

    +++++++++++++++++++++++++++++++++++

    (OTCBB:HNAB Hana Biosciences, Inc.)

    CURRENT NEWS!!

    Hana Biosciences Completes Pre-NDA Meeting With FDA for Marqibo in Adult Acute Lymphoblastic Leukemia

    SOUTH SAN FRANCISCO, Calif., Apr 27, 2010  Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the Company has completed a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) related to its lead product candidate, Marqibo for the treatment of relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). The purpose of the meeting was to discuss the proposed NDA and to confirm the clinical, non-clinical and manufacturing requirements for the NDA submission.

    Following the pre-NDA meeting, Hana intends to proceed with its plan to submit a rolling NDA for Marqibo in relapsed/refractory adult Philadelphia chromosome-negative ALL.

    About Marqibo(R) (vincristine sulfate liposomes injection)

    Marqibo is a novel, targeted, Optisome(TM) encapsulated formulation of vincristine sulfate, a widely-used chemotherapy, which has shown promising anti-cancer activity in patients with ALL, non-Hodgkin’s lymphoma, Hodgkin’s disease, and melanoma in several clinical trials. Marqibo is designed to enhance the penetration and concentration of vincristine sulfate at sites of active cancer and facilitate dose-intensification compared to standard vincristine formulations. Unlike standard vincristine, Marqibo is dosed based on actual patient body surface area without the need for dose-capping.

    Hana Biosciences has received orphan drug and fast track designations for Marqibo for the treatment of adult ALL from the U.S. Food and Drug Administration. Marqibo has also received orphan drug designation in adult ALL from the European Medicines Evaluation Agency.

    About Hana Biosciences

    Hana Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing new, differentiated cancer therapies designed to improve and enable current standards of care. The company’s lead product candidate, Marqibo(R), potentially treats acute lymphoblastic leukemia and lymphomas. The Company has additional pipeline opportunities, some of which, like Marqibo, improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

    ++++++++++++++++++++++++++++++

    (OTC: ARSC – American Security Resources Corp.)

    CURRENT NEWS !!

    Westor Capital Group to Place $1,000,000 in Notes for Hydra Production

    HOUSTON, Apr 26, 2010 American Security Resources Corporation (Pinksheets: ARSC) announced today that it has appointed New York based Westor Capital Group as Placement Agent to place a series of up to $1,000,000 in Senior Secured Notes with the proceeds to be used to start production at the Company’s Hydra Fuel Cell subsidiary.

    Bob Farr, President and COO of ARSC, stated, “Westor has already started to work on placing the Notes and Hydra is ready to ramp production when the first dollars arrive.”

    Westor Capital Group Inc.

    Westor Capital Group’s mission is to assist emerging growth companies and investors who follow them achieve success. Westor structures and arranges equity and debt financings for public companies, provides equity trading and execution for institutional and private clients, and offers comprehensive retail brokerage services.

    Westor’s seasoned professionals possess extensive experience in structuring and executing public and private transactions. Westor Capital has established a large and diverse network of funding sources by providing attractive and timely investment opportunities for its clients.

    Westor Capital Group Inc. is a member of FINRA and SIPC.

    For more information, please see: www.westorcapital.com

    American Security Resources Corporation

    ARSC is a holding company of clean energy technologies. ARSC, through its Hydra subsidiary, has developed high volume, mass producible hydrogen fuel cells. Its American Hydrogen Corp. subsidiary is developing methods to inexpensively formulate hydrogen.

    For more information, please see: www.americansecurityresources.com

    +++++++++++++++++++++++++++++

    (OTC: IGNT – Ingen Technologies, Inc.)

    CURRENT NEWS !!

    Letter From the Chairman of Ingen Technologies

    $200M Potential Annual Earnings at Reach

    YUCAIPA, Calif., Apr 27, 2010 Ingen Technologies, Inc. (Pink Sheets:IGNT), a medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S. and $8 billion globally, today announced the following letter to shareholders from CEO and Chairman of the Board, Scott R. Sand:

    “Ingen is on the verge of tremendous growth after enduring a number of regulatory and economic obstacles. In the face of economic headwinds, the company obtained both FDA and ISO Certification and launched several new and inspiring medical products in the respiratory market. As a result of this success, we have attracted many investors and new shareholders.

    Ingen has developed a global perspective on the markets in which we compete. First, we conducted a thorough market study for our products with InTouch Life Science Corporation, while at the same time filing patents and trademarks for our proprietary technology; second, we properly registered our products with the FDA and qualified the products for FDA export; third, we hired Emergo Group, a recognized global consulting firm that assisted us with the ISO 13485 Certification, CE Mark and distribution partners in order to comply with the world markets for distribution of our medical products; and finally, we hired KGMA Business Solutions, a leading consulting firm to prepare and file our GSA Contract, as well as develop government contracts with the VA Hospitals and Department of Defense. More important, we have lowered our production costs for our products, increased our margins and the margins of our distributors, while keeping a competitive edge on pricing our products in the challenging medical markets of today.

    This company has integrated growth partnership services into all your departments, divisions, and project teams. With 100 percent integration, the full benefits and value from teamwork, improved decision-making, and creativity will be realized. We have developed a growth culture which at first was an enormous challenge, and now has resulted as a clear vision, developing growth teams, opening communication, expanding an attitude of empowerment and leadership by example, pushing our various teams, raising the bar, and setting goals as a part of our role in leadership.

    Ingen has made changes to foster a growth culture with a clear vision for the future. With these successes and changes, the company has undergone a restructuring in order to align our incentives with that of our shareholders. The company is now keenly focused on growth, open communication, and leadership by example, as it works diligently to expand its sales and deliver shareholder value.

    Investing in our growth is a nominal expense to ensure that Ingen is working to maximize the growth potential of this company. With our past accomplishments of benchmarking our goals, we have learned that extraordinary companies have extraordinary goals. The company is presently strong and the future indicates strong potential.

    Ingen has started 2010 on a solid footing by achieving all of its goals and expects to end the year with $11 million in sales. Morevoer, we have taken steps to significantly reduce our debt with our note holders and anticipate a share buy-back program in June. By virtually every measure we have met or exceeded our objectives and positioned the company for a strong finish in 2010, as well as a sound future for the years to come.

    Our inspiration comes from many sources – our shareholders, customers and consumers, as well as our critics. Our staff and consulting team have a passion for what they do that ignites this inspiration every day, everywhere we do business. We remain fresh, relevant and original by knowing what to change without changing what we know. We are asking more questions, listening more closely, and collaborating more effectively with our partners, OEMs, the GPO, as well as distribution and strategic consultants to give our customers the product they need, and provide our shareholders with the results that they deserve.”

    About  Ingen Technologies, Inc.

    Ingen is an ISO Certified medical device manufacturer with oxygen therapy products for the respiratory care markets. These products include a proprietary pneumatic oxygen flow meter referred to as “Oxyview”, and the “SMART Nasal Cannula”. The newest product was introduced in January of 2010 referred to as the “INGEN Pulse Oximeter”. The respiratory care market is worth an estimated $4 Billion in the US, and $8 billion globally. The oxygen nasal cannula market represents $400M of this market.The company introduced its first Oxyview product in late 2007 after securing US and Foreign Patents and successful classification with the Food & Drug Administration, and licensing with the Department of Health & Human Services. In 2009, the company introduced the Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government sources. Ingen manufacturers their respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million COPD patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

    

    April 27, 2010 @ 2:17 pm Trackback URL Posted in Hot Stocks and tagged with , , , , , , , , , , , , , , , .